Continuation of chemotherapy versus supportive care alone in patients with inoperable non‐small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study

摘要: Recommendations concerning the continuation of chemotherapy in nonresponding patients with non-small cell lung cancer (NSCLC) and stable disease after first test are empirical often conflicting. Between 1984 1987, 116 inoperable NSCLC were treated methothrexate, doxorubicin, cyclophosphamide, lomustine (MACC regimen). After two or three cycles therapy, 74 judged to have assigned at random either maintenance same regimen (38 subjects) discontinuation (36 subjects). The study groups comparable for all major prognostic factors. Median time progression was 26 weeks group compared 24 nonchemotherapy (P = NS). survival prolonged treatment arm (47 weeks) nontreatment (30 weeks), which statistically nonsignificant. A patient self-assessment quality life revealed a significantly worse tolerance therapy better physical condition group. Objective MACC toxicity significant treatment-related deaths. This failed demonstrate sufficient therapeutic benefits justify increased cost continuing patients.